{"title":"Teicoplanin total trough concentration and adverse effects in patients with hypoalbuminemia","authors":"Hirofumi Oishi , Yoshimichi Koutake , Narumi Ebata , Yoji Nagasaki , Masashi Hashimoto","doi":"10.1016/j.jiac.2025.102807","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The association between Teicoplanin (TEIC) total trough concentration (C<sub>min</sub>) and adverse effects (hepatotoxicity, nephrotoxicity, and thrombocytopenia) in patients with hypoalbuminemia remains poorly understood. We examined this association for patients with hypoalbuminemia from a safety perspective.</div></div><div><h3>Methods</h3><div>This retrospective study included adult patients (≥18 years) who received TEIC at Kyushu Medical Center between April 2013 and March 2024, underwent therapeutic drug monitoring, and had persistent serum albumin <2.5 g/dL. The primary outcome was the occurrence of hepatotoxicity, nephrotoxicity, and thrombocytopenia. Multivariate logistic regression analysis evaluated the association between TEIC C<sub>min</sub> and each adverse event.</div></div><div><h3>Results</h3><div>Hepatotoxicity, nephrotoxicity, and thrombocytopenia were reported in 13.5 % (33/245), 19.0 % (42/221), and 14.4 % (22/153) of patients, respectively. TEIC C<sub>min</sub> ≥ 21.1 μg/mL, serum albumin <2.0 g/dL, and total parenteral nutrition were associated with hepatotoxicity. Hepatitis/liver cirrhosis and vasopressor use were associated with nephrotoxicity. The factors associated with thrombocytopenia included estimated glomerular filtration rate <30 mL/min/1.73 m<sup>2</sup>, platelet counts ≤150 × 10<sup>3</sup>/μL, hyperuricemia, and hematologic disorders.</div></div><div><h3>Conclusions</h3><div>Our findings suggest that a TEIC C<sub>min</sub> ≥ 21.1 μg/mL may increase the risk of TEIC-induced hepatotoxicity in patients with hypoalbuminemia. These findings may need to be validated in further studies.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 10","pages":"Article 102807"},"PeriodicalIF":1.5000,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Infection and Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1341321X25002041","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Background
The association between Teicoplanin (TEIC) total trough concentration (Cmin) and adverse effects (hepatotoxicity, nephrotoxicity, and thrombocytopenia) in patients with hypoalbuminemia remains poorly understood. We examined this association for patients with hypoalbuminemia from a safety perspective.
Methods
This retrospective study included adult patients (≥18 years) who received TEIC at Kyushu Medical Center between April 2013 and March 2024, underwent therapeutic drug monitoring, and had persistent serum albumin <2.5 g/dL. The primary outcome was the occurrence of hepatotoxicity, nephrotoxicity, and thrombocytopenia. Multivariate logistic regression analysis evaluated the association between TEIC Cmin and each adverse event.
Results
Hepatotoxicity, nephrotoxicity, and thrombocytopenia were reported in 13.5 % (33/245), 19.0 % (42/221), and 14.4 % (22/153) of patients, respectively. TEIC Cmin ≥ 21.1 μg/mL, serum albumin <2.0 g/dL, and total parenteral nutrition were associated with hepatotoxicity. Hepatitis/liver cirrhosis and vasopressor use were associated with nephrotoxicity. The factors associated with thrombocytopenia included estimated glomerular filtration rate <30 mL/min/1.73 m2, platelet counts ≤150 × 103/μL, hyperuricemia, and hematologic disorders.
Conclusions
Our findings suggest that a TEIC Cmin ≥ 21.1 μg/mL may increase the risk of TEIC-induced hepatotoxicity in patients with hypoalbuminemia. These findings may need to be validated in further studies.
期刊介绍:
The Journal of Infection and Chemotherapy (JIC) — official journal of the Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases — welcomes original papers, laboratory or clinical, as well as case reports, notes, committee reports, surveillance and guidelines from all parts of the world on all aspects of chemotherapy, covering the pathogenesis, diagnosis, treatment, and control of infection, including treatment with anticancer drugs. Experimental studies on animal models and pharmacokinetics, and reports on epidemiology and clinical trials are particularly welcome.